Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells

Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety

(2015) M. Aapro et al.   ONCOLOGIST

Glioblastoma multiforme: Pathogenesis and treatment

(2015) Constantinos Alifieris et al.   PHARMACOLOGY & THERAPEUTICS

HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress

(2015) Runping Liu et al.   PLoS One

The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies

(2015) Akinori Sato   OncoTargets and Therapy

The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors

(2015) Sandra Liekens et al.   Oncotarget

Nuclear translocation of fibroblast growth factor-2 (FGF2) is regulated by Karyopherin-β2 and Ran GTPase in human glioblastoma cells

(2015) Feng Wang et al.   Oncotarget

Quantification of Central Substance P Receptor Occupancy by Aprepitant Using Small Animal Positron Emission Tomography

(2015) T. Endo et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

(2015) Richard E. Kast et al.   Oncotarget

CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide

(2015) Richard E. Kast et al.   Oncotarget

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

(2014) S. Dalva-Aydemir et al.   CLINICAL CANCER RESEARCH

Preclinical evidence that SSR128129E – A novel small-molecule multi-fibroblast growth factor receptor blocker – Radiosensitises human glioblastoma

(2014) Isabelle Ader et al.   EUROPEAN JOURNAL OF CANCER

Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells

(2014) Jingchao Wu et al.   JOURNAL OF NEURO-ONCOLOGY

Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors

(2014) Elizabeth Harford-Wright et al.   PLoS One

Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage

(2013) Tim De Schutter et al.   BMC Medical Genomics

The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture

(2013) Elizabeth M. Haley et al.   CANCER LETTERS

Cidofovir: A Novel Antitumor Agent for Glioblastoma

(2013) P. Hadaczek et al.   CLINICAL CANCER RESEARCH

Safety of neurokinin-1 receptor antagonists

(2013) Miguel Muñoz et al.   Expert Opinion On Drug Safety

Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations

(2013) Marianne Kraus et al.   LEUKEMIA RESEARCH

Involvement of substance P and the NK-1 receptor in cancer progression

(2013) Miguel Muñoz et al.   PEPTIDES

Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells

(2012) F. Rappa et al.   BIOCHIMIE

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types

(2012) Matti S. Aapro et al.   CANCER TREATMENT REVIEWS

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals

(2010) Mark M Manak et al.   AIDS

Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug

(2010) R. E. Kast   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question

(2009) Richard E. Kast   Clinical & Translational Oncology

Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study

(2009) C. Van Pachterbeke et al.   GYNECOLOGIC ONCOLOGY

The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug

(2009) Miguel Muñoz et al.   INVESTIGATIONAL NEW DRUGS

A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas

(2009) Toshimasa Akazawa et al.   JOURNAL OF NEUROCHEMISTRY

Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection

(2008) Sharon S. Lieberman-Blum et al.   CLINICAL THERAPEUTICS

Anti-HIV drugs for cancer therapeutics: back to the future?

(2008) Warren A Chow et al.   LANCET ONCOLOGY